Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis

Nature Genetics

Volumn 32, Issue 2, 2002, Pages 306-311

  Bernal, Juan A ^a   Luna, Rosa ^a   Espina, Águeda ^a   Lázaro, Icíar ^b   Ramos Morales, Francisco ^c   Romero, Francisco ^c   Arias, Carmen ^b   Silva, Augusto ^b   Tortolero, María ^c   Pintor Toro, José A ^a  

^a INSTITUTO DE RECURSOS NATURALES Y AGROBIOLOGÍA DE SEVILLA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN CUT2P; PROTEIN P53; PROTEIN PDS1P; SECURIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; GENE ISOLATION; GENE OVEREXPRESSION; HUMAN; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; GENE LIBRARY; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; PEPTIDE LIBRARY; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; SACCHAROMYCETALES; SCHIZOSACCHAROMYCES POMBE;

EID: 0036788641     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng997     Document Type: Article

References (30)

1. Dominguez, A. et al. hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17, 2187-2193 (1998).
2. Jallepalli, P.V. et al. Securin is required for chromosomal stability in human cells. Cell 105, 445-457 (2001).
3. Saez, C. et al. hpttg is overexpressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18, 5473-5476 (1999).
4. Zhang, X. et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 13, 156-166 (1999).
5. Zou, H., McGarry, T,J., Bernal, T. & Kirschner, M.W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285, 418-422 (1999).
6. Ramos-Morales, F. et al. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19, 403-409 (2000).
7. Loeb, L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079 (1991).
8. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
9. Lengauer, C., Kinzler, K.W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649 (1998).
10. Pei, L. Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J. Biol. Chem. 276, 8484-8491 (2000).
11. Mei, J., Huang, H. & Zhang, P. Securin is not required for cellular viability, but is required for normal growth of mouse embryonic fibroblasts. Curr. BioL 11, 1197-1201 (2001).
12. Wang, Z., Yu, R. & Melmed, S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol. Endocrinol. 15, 1870-1879 (2001).
13. Romero, F. et al. Human securin/hPTTG is associated with the DNA-dependent protein kinase. Nucleic Acids Res. 29, 1300-1307 (2001).
14. Hoogenboom, H.R. et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19, 4133-4137 (1991).
15. Bargonetti, J., Reynisdóttir, I., Friedman, P.N. & Prives, C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6, 1886-1998 (1992).
16. Green, D.R. & Reed, J.C. Mitochondria and apoptosis. Science 281, 1309-1312 (1998).
17. Hermeking, H. et al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1, 3-11 (1997).
18. El-Deiry, W.S. et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 75, 817-925 (1993).
19. Oliner, J.D. et al. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362, 857-860 (1993).
20. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
21. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
22. Heaney, A.P. et al. Expression of pituitary-tumor transforming gene in colorectal tumors. Lancet North Am. Ed. 355, 716-719 (2000).
23. Vousden, K.H. p53: death star. Cell 103, 691-694 (2000).
24. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
25. Owen-Schaub, L.B. et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15, 3032-3040 (1995).
26. Schmitt, C.A. & Lowe, S.W. Apoptosis and therapy. J. Pathol. 187, 127-137 (1999).
27. Soengas, M.S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
28. Raman, V. et al. Compromised HOXA5 function can limit p53 expression in human breast tumors. Nature 405, 974-978 (2001).
29. O'Connor, D.J. et al. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J 14, 6184-6192 (1995).
30. Zhu, L. et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 7, 1111-1125 (1993).